Partnering with You to

Deliver Scientific Insight

We are excited to inform you that LabCorp’s Covance Drug Development segment and Sciformix have completed the previously announced transactions that will strengthen and enhance the way our respective businesses support the life sciences industry. Sciformix’s brand recognition and leadership in the pharmacovigilance industry greatly expands Covance’s global pharmacovigilance footprint and offerings, already strengthened through the previous acquisition of Chiltern, with end-to-end PV services and supporting technologies, additional locations and resources. This exciting combination creates an organization with significant global scale and a full suite of PV capabilities across the entire product lifecycle from early stage development through commercialization.